SLEEP 2026 Meeting
Five Takeaways That Leave Me Optimistic About the Future of Sleep Medicine
This was my first time attending the AASM annual SLEEP meeting, and it won’t be the last. The feedback I heard from many attendants is this is the biggest and most excitement at the meeting in a long time. It wasn’t just the packed lecture halls or the bustling exhibit floor. It was the conversations—in sessions, in hallways, and around dinner tables—that suggested sleep medicine has reached an inflection point.
For years we’ve talked about the big changes coming. At SLEEP 2026, it felt like that future is finally arriving.
1. Sleep medicine is becoming one of the most exciting areas in healthcare
Several attendees commented on the size of the meeting and the energy throughout the conference. I certainly felt it as well. Across nearly every sleep disorder, innovation is accelerating:
Novel pharmacologic targets
Rapid advances in wearable technology
New surgical approaches
Better diagnostics
Artificial intelligence
Increasing investment from industry
Perhaps most importantly, there is growing recognition from outside sleep medicine that sleep is foundational to overall health. Public awareness campaigns, consumer wearables, social media, and attention from large healthcare companies are bringing entirely new patients into clinics.
For a specialty that has often felt overlooked, this is an exciting moment.
2. Obstructive sleep apnea is entering the era of precision medicine
One recurring theme throughout the meeting was that the field is firmly moving beyond AHI/CPAP dogma.
Researchers and clinicians increasingly emphasized the evidence such as hypoxic burden, phenotyping scores (like Dr. Danny Eckert’s PALM score), on top of quality of life, and long-term disease management as helping to guide treatment discussions.
This also came through in conversations surrounding alternative treatments, including surgery. There was significant interest in multidisciplinary care, the potential for pharmacological therapy (especially GLP’s and Apnimed’s AD109), and novel hypoglossal nerve stimulation options.
We continue to acknowledge the utility of both AHI/CPAP, but there is easier transition to thinking how other options can supplement both.
3. Pharmacotherapy is no longer a future concept—it’s becoming reality
If there was one topic discussed everywhere, it was medication.
Apnimed generated enormous interest both during scientific sessions and in hallway conversations as clinicians begin thinking about where oral pharmacotherapy may fit into clinical practice. FDA review is expected in early 2027!
Looking ahead, several next-generation therapies are already on the horizon, including Mosanna’s MOS118 program entering clinical studies later this year and continued excitement surrounding orexin-targeted therapies from Takeda and others.
Meanwhile, the TRIUMPH-OSA data with retatrutide (Eli Lilly) reinforced that metabolic therapies are likely to become an increasingly important part of treating obstructive sleep apnea.
The conversation has clearly shifted from if medications will have a role in OSA, to how large a role and what populations are best suited for them.
4. Wearables are changing how we think about diagnosis, workflows, and follow-up
One of the most interesting discussions I participated in was an industry roundtable that brought together leaders from across the sleep ecosystem—including diagnostics, CPAP manufacturers, implantable therapies, pharmaceutical companies, clinicians, and patient advocates.
Rather than debating individual products, much of the conversation focused on where the field is headed.
A major theme was the role of wearable technology and multi-night assessment.
Instead of relying on a single night of testing, future care may increasingly incorporate longitudinal data collected before treatment, during therapy, and over time. This could help clinicians better understand individual patient response, personalize therapy, and monitor long-term disease control.
It is also likely that wearables will continue improving and serving as an initial impetus for patients to seek care. Given limited bandwidth by sleep physicians/surgeons, this is another topic to keep an eye on.
5. The biggest winners will be patients
Perhaps the most encouraging takeaway from SLEEP 2026 is that patients have more choices than ever before.
Not every patient wants CPAP or even NEEDS CPAP.
But increasingly, the questions aren’t either/or. The future of sleep medicine is multidisciplinary, personalized, and in many cases multimodal. As our understanding of OSA biology improves and our therapeutic toolbox expands, we can focus less on finding a single “best” treatment and more on reducing disease burden in ways that matter to individual patients.
That represents a remarkable shift from where the field stood even five years ago.
Final thoughts
Leaving SLEEP 2026, I found myself more optimistic than ever about where sleep medicine is heading.
The science is improving. The treatment options are expanding. Industry investment continues to grow. Most importantly, our conversations are becoming more patient-centered—focusing not simply on lowering an AHI, but on improving their lives.
For clinicians, researchers, industry partners, and patients alike, this feels like the beginning of a very exciting chapter.
We look forward to tracking these developments and their impact on physicians and patients.
-Chris & Robson.